DOPAMINE METABOLISM IN THE CENTRAL NERVOUS-SYSTEM AFTER DISCONTINUATION OF L-DOPA THERAPY IN PATIENTS WITH PARKINSON DISEASE

被引：49
|
作者：
OGASAHARA, S
NISHIKAWA, Y
TAKAHASHI, M
WADA, K
NAKAMURA, Y
YORIFUJI, S
TARUI, S
机构：
来源：
JOURNAL OF THE NEUROLOGICAL SCIENCES | 1984年 / 66卷 / 2-3期
关键词：
D O I：
10.1016/0022-510X(84)90003-0
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：151 / 163
页数：13
相关论文
共 50 条
  • [1] EFFECTS OF L-DOPA ON POLYAMINE METABOLISM IN CENTRAL NERVOUS-SYSTEM OF RAT
    HARIK, SI
    ANNALS OF NEUROLOGY, 1977, 1 (05) : 506 - 506
  • [2] Plasma homocysteine and L-DOPA metabolism in patients with Parkinson disease
    Blandini, F
    Fancellu, R
    Martignoni, E
    Mangiagalli, A
    Pacchetti, C
    Samuele, A
    Nappi, G
    CLINICAL CHEMISTRY, 2001, 47 (06) : 1102 - 1104
  • [3] Autonomic nervous system response to L-dopa in patients with advanced Parkinson's disease
    Ruonala, Verneri
    Tarvainen, Mika P.
    Karjalainen, Pasi A.
    Pekkonen, Eero
    Rissanen, Saara M.
    2015 37TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY (EMBC), 2015, : 6162 - 6165
  • [4] EEG CHANGES BEFORE AND AFTER L-DOPA THERAPY IN PARKINSON PATIENTS
    TAUBER, J
    WAJSBORT, J
    ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY, 1973, 34 (07): : 784 - 785
  • [5] In vivo assessment of Intrasynaptic dopamine in Parkinson patients following treatment with L-dopa or L-dopa/entacapone
    Seibyl, JP
    Tabamo, R
    Jennings, D
    Tamagnan, G
    Rabinowicz, A
    Marek, K
    MOVEMENT DISORDERS, 2005, 20 : S44 - S45
  • [6] L-Dopa Responsiveness is Correlated to Fluorodeoxyglucose Metabolism and Dopamine Transporter Availability in Parkinson's Disease
    Su, D.
    Hu, W.
    Zhao, X.
    Liu, Z.
    Ma, H.
    Zhou, J.
    Feng, T.
    MOVEMENT DISORDERS, 2018, 33 : S697 - S698
  • [7] MEASURING L-DOPA IN PLASMA AND URINE TO MONITOR THERAPY OF ELDERLY PATIENTS WITH PARKINSON DISEASE TREATED WITH L-DOPA AND A DOPA DECARBOXYLASE INHIBITOR
    DUTTON, J
    COPELAND, LG
    PLAYFER, JR
    ROBERTS, NB
    CLINICAL CHEMISTRY, 1993, 39 (04) : 629 - 634
  • [8] DOPAMINE 3-O-SULPHATE, AN END PRODUCT OF L-DOPA METABOLISM IN PARKINSON PATIENTS
    JENNER, WN
    ROSE, FA
    NATURE, 1974, 252 (5480) : 237 - 238
  • [9] Duration of L-dopa and dopamine agonist monotherapy in Parkinson's disease
    Nissen, T.
    Newman, E. J.
    Grosset, K. A.
    Daghem, M.
    Pal, G.
    Stewart, M.
    Odin, P.
    Macphee, G. J.
    Grosset, D. G.
    MOVEMENT DISORDERS, 2011, 26 : S259 - S259
  • [10] Duration of L-dopa and dopamine agonist monotherapy in Parkinson's disease
    Nissen, T.
    Newman, E. J.
    Grosset, K. A.
    Daghem, M.
    Pal, G.
    Stewart, M.
    Odin, P.
    Macphee, G. J.
    Grosset, D. G.
    SCOTTISH MEDICAL JOURNAL, 2012, 57 (04) : 217 - 220
12345